Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.

Morgan Stanley estimates the obesity drug market could rise from ~$15B in 2024 to as much as ~$150B by 2035, which the article frames as a decade-long tailwind for Eli Lilly. It notes Foundayo (oral pill) launched in the U.S. in April and Retatrutide could provide additional growth catalysts, with earnings modeled from $35.60/share (2026 consensus) to ~$125.23/share in year 10 under a 15% annual growth assumption. With shares trading at 34x 2026 earnings today, the article argues upside of ~158% over the next decade (excluding dividends) even if the multiple compresses to 25x.

Analysis

The key market mechanism is not whether obesity demand grows — it likely does — but who captures the incremental economics. LLY has the best mix of scale, formulation breadth, and pipeline optionality, yet that also means it is the consensus compounder and already carries the highest expectation burden in large-cap pharma. In a market that can expand rapidly, the first-order winner can still become a relative underperformer if gross-to-net rebates rise, payer access tightens, or the category starts to look more like a durable franchise than a scarcity story.

The next 1-3 months matter more for sentiment than for fundamentals: prescription trends, commentary on oral adoption, and any signal on manufacturing or payer mix will drive multiple support. The more important 6-18 month catalyst is retatrutide data/filing timing; if it slips or safety/tolerability narrows its commercial ceiling, the stock’s premium multiple is vulnerable even if revenue still grows at a strong clip. That asymmetry argues for watching the spread between top-line growth and valuation expansion rather than assuming every increment of market growth translates into equity upside.

Contrarian view: the consensus is likely underestimating how much competition the category can absorb before pricing power deteriorates. NVO is not a clean loser here; if the oral market broadens adoption, the company can still participate in category growth even while fighting for share. The bigger risk to LLY is not demand exhaustion but expectations compression — a modest miss in any one of launch cadence, adherence, or pipeline timing could cause multiple contraction faster than EPS growth can offset it.

Key Decisions for Investors

• Avoid initiating a fresh outright long in LLY at current levels; the setup is better as a hold than a new high-conviction buy until the market proves retatrutide timing and gross-to-net stability. Falsifier: if management reaccelerates guidance and access remains broad, re-rate higher is possible.
• Relative-value trade: long NVO / short LLY over the next 1-3 months to express the view that consensus overpays for LLY’s certainty while underpricing NVO’s catch-up potential if oral adoption broadens. Stop if LLY prints a clean prescription-share gain and raises 2026/2027 guidance.
• If you want upside exposure, use call spreads instead of stock: LLY 12-18 month call spreads financed against the current valuation premium to define downside. The trade works only if retatrutide catalyst timing stays intact and the market accepts >20% long-run EPS growth.
• Set an alert for any evidence of payer pushback or slower refill persistence in obesity scripts; that is the earliest signal that market growth is real but monetization is weaker than the sell-side model implies.